Deal Complicates Rights to Big Drug

The issue centers on the anti-inflammatory drug Remicade, which J&J and Schering-Plough co-market. J&J handles U.S. marketing, and Schering sells it outside the U.S. The agreement, which dates to the 1990s, covers a new drug, golimumab, expected to go on sale later this year. As part of the partnership, J&J has the opportunity to acquire full rights to the drugs if Schering-Plough were to be taken over.